Changes in medical oncology admissions for the management of breast cancer complications: An Australian institution's experience

Day, Fiona; Bull, James; Lombard, Janine; Stewart, John

doi:10.1111/j.1743-7563.2011.01391.x

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study described 83 patients with MBC who were admitted to a medical oncology inpatient unit in Australia and demonstrated that only approximately 15% of admissions in 2006 received a palliative care consult. 25 Our study confirms the low rates of palliative care and hospice utilization in this population. By focusing on patients hospitalized for the first time with MBC, we have identified a distinct event in these patients’ course of illness for clinicians to consider which patients may benefit from palliative care and hospice services.…”

Section: Discussionsupporting

confidence: 83%

“…Despite the high symptom burden and poor prognosis of patients in this study, palliative care was consulted in only 6.8% of admissions, and 18% of patients enrolled in hospice upon discharge. Another study described 83 patients with MBC who were admitted to a medical oncology inpatient unit in Australia and demonstrated that only approximately 15% of admissions in 2006 received a palliative care consult (25). Our study confirms the low rates of palliative care and hospice utilization in this population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective evaluation of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer

et al. 2016

View full text Add to dashboard Cite

Background Hospitalizations in patients with metastatic cancer occur commonly at the end of life but have not been well-described in individuals with metastatic breast cancer. Aim To describe the reasons for admission and frequency of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer. Design This was a retrospective chart review of patients who had their first hospitalization with a diagnosis of metastatic breast cancer between 1/1/2009 and 12/31/2010. To standardize follow-up time, we collected data for three years post the index hospitalization. Setting/participants We identified 123 consecutive patients who were hospitalized for the first time with a diagnosis of metastatic breast cancer at a single, tertiary care center. Results Uncontrolled symptoms accounted for half (50%, 62/123) of index admissions. The majority of patients died during the follow-up period (76%, 94/123), and the median time from index admission to death was six months (range, 0 to 34). Approximately half (53%, 50/94) died in the hospital or within 14 days of last hospital discharge, and less than one-third (29%, 27/94) were referred to hospice after their last hospitalization. The inpatient palliative care team evaluated 57% (54/94) of those who died at least once during an admission, but only 17% (16/94) of patients attended an outpatient palliative care appointment. Conclusions Hospitalized patients with metastatic breast cancer are commonly admitted for uncontrolled symptoms and have a poor prognosis. However, only a minority receive outpatient palliative care or are referred to hospice during their last hospitalization prior to death.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Most patients presenting with non‐neutropenic fever were managed as outpatients (82%), while nearly all presentations with neutropenic fever resulted in hospital admission (93%). Due to the potential sequelae of life‐threatening sepsis, neutropenic fever is the ED presentation reason most likely to result in hospital admission, both in early breast cancer patients and the broader cancer population . Neutropenic fever accounted for a higher proportion of ED presentations in our study (24%) than in early breast cancer patients in Canada (9%) .…”

Section: Discussionmentioning

confidence: 65%

Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy

Tang

Horsley

Lewis

2018

Internal Medicine Journal

View full text Add to dashboard Cite

(Neo)adjuvant chemotherapy for early stage breast cancer is associated with side‐effects, resulting in increased emergency department (ED) presentations. Treatment‐related toxicity can affect quality of life, compromise chemotherapy delivery and treatment outcomes, and increase healthcare use. We performed a retrospective study of ED presentations in patients receiving curative chemotherapy for early breast cancer to identify factors contributing to ED presentations. Of 102 patients, 39 (38%) presented to ED within 30 days of chemotherapy, resulting in 63 ED presentations in total. Most common reasons were non‐neutropenic fever (17 presentations/27%), neutropenic fever (15/24%), pain (9/14%), drug reaction (6/10%) and infection (4/6%). Factors significantly associated with ED presentation were adjuvant chemotherapy timing compared to neoadjuvant timing (P = 0.031), prophylactic antibiotics (P = 0.045) and docetaxel‐containing regimen (P = 0.018).

show abstract

“…Rates of admission to hospital with serious complications have mostly been reported to be in the range 20% to 25% [5][6][7] and there is a small risk of early death from treatment, reported to be in the range 0.2% to 0.3% in recent studies. 8,9 Patients are frequently unable to work both during treatment and for some time thereafter, 10 which has considerable cost to society.…”

Section: Chapter 1 Backgroundmentioning

confidence: 99%

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Stein

Dunn²,

Bartlett

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 10/34/01. The contractual start date was in May 2012. The draft report began editorial review in May 2014 and was accepted for publication in September 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Background: There i...

show abstract

Changes in medical oncology admissions for the management of breast cancer complications: An Australian institution's experience

Cited by 5 publications

References 30 publications

Retrospective evaluation of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer

Retrospective evaluation of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer

Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Contact Info

Product

Resources

About